Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
IXICO plc ( (GB:IXI) ) has provided an announcement.
IXICO reported a 23% rise in interim revenues to £3.9 million, driven by new contracts, extensions and higher analysis volumes in its imaging CRO business, while gross margin improved to 53% and EBITDA losses narrowed to £0.5 million. The order book climbed 38% year-on-year to £18.1 million, supported by later-stage trial wins and expansion into blood-based biomarker validation, reinforcing its position as a neuroscience precision-medicine specialist.
The company is pivoting further into a TechBio model by leveraging its IXI™ platform, highlighted by a post-period £10 million capital raise to fund integration with partners across the clinical ecosystem. A new collaboration with Medidata, deployment of the latest IXI™ platform version, global operational expansion and the appointment of a U.S.-based chief commercial officer are intended to unlock new revenue streams and strengthen IXICO’s competitive standing in neurodegenerative disease research.
Spark’s Take on IXI Stock
According to Spark, TipRanks’ AI Analyst, IXI is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and negative operating cash flow) and very bearish technicals (below key moving averages with negative MACD). A positive offset comes from supportive earnings-call guidance and order book growth, but valuation remains constrained by the company’s loss-making profile.
To see Spark’s full report on IXI stock, click here.
More about IXICO plc
IXICO plc is a U.K.-based neuroscience-focused imaging contract research organisation that provides AI-driven imaging and biomarker analytics to support drug development in neurological disorders. Its proprietary IXI™ platform processes imaging and biomarker data from global clinical trials in diseases such as Alzheimer’s, Huntington’s and Parkinson’s, working with major pharmaceutical, biotech and research partners worldwide.
Average Trading Volume: 148,162
Technical Sentiment Signal: Sell
Current Market Cap: £14.72M
See more data about IXI stock on TipRanks’ Stock Analysis page.